Search - tctmd.com

Displaying 1 - 20 of 1290

Sort: Relevancy | Date

DIG-RHD: Digoxin Effective in Rheumatic Heart Disease

News Conference News ACC 2026

DIG-RHD: Digoxin Effective in Rheumatic Heart Disease

Michael O'Riordan

April 06, 2026

Despite Guidelines, Aspirin Is Used in Fewer Than One in Four High-risk Pregnancies

News Conference News ACC 2026

Despite Guidelines, Aspirin Is Used in Fewer Than One in Four High-risk Pregnancies

Yael L. Maxwell

April 03, 2026

Clinician EHR Alerts Lead to Speedier Evaluation, Treatment of Valve Disease

News Conference News ACC 2026

Clinician EHR Alerts Lead to Speedier Evaluation, Treatment of Valve Disease

April 01, 2026

SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

News Conference News ACC 2026

SCOUT-HCM: Mavacamten Can Benefit Teens With Obstructive HCM, Too

March 30, 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

News Conference News ACC 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Yael L. Maxwell

March 30, 2026

Transcatheter ViV a Solid Option for Failed Mitral Bioprostheses: SURViV

News Conference News ACC 2026

Transcatheter ViV a Solid Option for Failed Mitral Bioprostheses: SURViV

March 30, 2026

SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF

News Conference News ACC 2026

SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF

March 29, 2026

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

News Conference News ACC 2026

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Michael O'Riordan

March 29, 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

News Conference News

Now Published: LAAO Doesn’t Match Medical Therapy for High-risk AF Patients in CLOSURE-AF

March 18, 2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR

News Conference News CRT 2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR

Michael O'Riordan

March 11, 2026

AI for Heart Failure Care Is Evolving Rapidly, THT 2026 Makes Clear

News Conference News THT 2026

AI for Heart Failure Care Is Evolving Rapidly, THT 2026 Makes Clear

March 10, 2026

Should Moderate FMR Should Be Treated With M-TEER? Experts Duke It Out

News Conference News THT 2026

Should Moderate FMR Be Treated With M-TEER? Experts Duke It Out

March 06, 2026

Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

News Conference News THT 2026

Baroreflex Activation for Advanced HF Yields Positive Results: Postmarketing Data

March 05, 2026

NT-proBNP Provides Info on Who Will Fare Well After Tricuspid TEER

News Conference News THT 2026

NT-proBNP Provides Info on Who Will Fare Well After Tricuspid TEER

March 04, 2026

SCAD-Related MI Not Just the Domain of Young Women: Serbian Registry

News Conference News EAPCI 2026

SCAD-Related MI Not Just the Domain of Young Women: Serbian Registry

February 27, 2026

AVR in Asymptomatic AS: Look to the ‘Sweet Spot’ for Timing

News Conference News EAPCI 2026

AVR in Asymptomatic AS: Look to the ‘Sweet Spot’ for Timing

February 25, 2026

THT 2026: What to Expect in Boston

News Conference News THT 2026

THT 2026: What to Expect in Boston

February 23, 2026

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.